

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/063887 A1

(51) International Patent Classification:

C07K 14/755 (2006.01) C07K 7/64 (2006.01)
A61K 38/08 (2019.01) C07K 14/76 (2006.01)
A61K 38/10 (2006.01) C07K 14/79 (2006.01)
A61K 38/12 (2006.01) C07K 17/00 (2006.01)
A61P 7/04 (2006.01) A61K 47/64 (2017.01)
C07K 7/06 (2006.01) A61K 39/00 (2006.01)
C07K 7/08 (2006.01) A61K 47/68 (2017.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2021/076182

(22) International Filing Date:

23 September 2021 (23.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20197701.4 23 September 2020 (23.09.2020) EP

(71) Applicant: **ABLEVIA BIOTECH GMBH** [AT/AT];
Maria-Jacobi-Gasse 1, 1030 Wien (AT).

(72) Inventors: **SMRZKA, Oskar**; c/o Ablevia biotech GmbH,
Maria-Jacobi-Gasse 1, 1030 Wien (AT). **WANKO, Bettina**;
c/o Ablevia biotech GmbH, Maria-Jacobi-Gasse 1, 1030
Wien (AT).

(74) Agent: **SONN PATENTANWÄLTE OG**; Riemergasse
14, 1010 Wien (AT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOUND FOR INCREASING THE EFFICACY OF FACTOR VIII REPLACEMENT THERAPY

(57) Abstract: The present invention provides a compound for the sequestration of undesirable antibodies associated with hemophilia A, in particular when treated by factor VIII replacement therapy. The compound comprises a biopolymer scaffold and at least two peptides derived from factor VIII with a sequence length of 6-13 amino acid, wherein each of the peptides independently comprises a 6-amino-acid fragment of the amino-acid sequence of factor VIII, optionally wherein at most three, preferably at most two, more preferably at most one amino acid is independently substituted by any other amino acid. Also provided are pharmaceutical compositions comprising the compound, as well as methods for treating hemophilia A.

WO 2022/063887 A1